Intrapleural tPA + DNase Therapy for Loculated Parapneumonic Effusion/Empyema

Indications

• In adults with loculated parapneumonic effusion or empyema that remains inadequately drained after chest‑tube placement, initiate intrapleural combination therapy with tissue‑type plasminogen activator (tPA) and dornase alfa (DNase) 【1, 2】.

Standard Dosing Regimen

• The evidence‑based protocol is tPA 10 mg twice daily plus DNase 5 mg twice daily for three consecutive days, administered through the existing chest tube 【1, 2】.
• Therapy should start after the initial drainage has slowed or stopped while a residual pleural collection is still present 【1】.
• Each dose is clamped for a dwell time of 1–2 hours, then the tube is reopened to suction 【2】.

Alternative Lower‑Dose Regimen

• A reduced dose of tPA 5 mg twice daily with DNase 5 mg twice daily for three days may achieve comparable efficacy, based on retrospective data, and can be considered when bleeding risk is a concern 【1, 2】.

Pre‑Treatment Requirements

• Obtain informed consent that specifically addresses the risk of bleeding 【1, 2】.
• Ensure a small‑bore chest tube (≤14 F) is already in place 【1, 2】.
• Verify that drainage from the initial chest‑tube placement alone is inadequate 【1】.

Administration Technique

• Instill the prescribed dose through the chest tube, clamp for 1–2 hours, then resume continuous suction at –10 to –20 cm H₂O 【2, 3】.

Dose Adjustments & Contraindications

• Reduce the tPA dose to 5 mg (instead of 10 mg) in patients receiving therapeutic anticoagulation that cannot be temporarily stopped 【1, 2】.
• Consider a reduced tPA dose in any patient with additional factors that increase bleeding risk 【1】.
• Absolute contraindications include recent neurosurgery or stroke 【1】.

Therapeutic Principles

• Single‑agent therapy (tPA alone or DNase alone) does not improve clinical outcomes and should be avoided 【1, 2】.
• Streptokinase should not be used because it raises post‑treatment complications without benefit 【1, 2】.

Expected Clinical Benefits

• The combination shortens hospital length of stay compared with placebo 【2】.
• It lowers the likelihood of persistent fever 【2】.
• Radiographic clearance of pleural opacification is improved 【2】.

Criteria for Surgical Referral

• Refer for video‑assisted thoracoscopic surgery (VATS) if there is no clinical improvement after 2–3 days of tPA/DNase therapy, with a persistent moderate‑to‑large effusion and ongoing respiratory compromise 【3】.
• When surgery is required, VATS is preferred over thoracotomy, offering a 2.3‑day shorter hospital stay, less postoperative pain, fewer complications, and slightly lower mortality 【1】.

Alternative When tPA/DNase Unavailable

• Saline irrigation (250 mL three times daily) may be considered as a rescue measure, although supporting evidence is limited 【1, 2】.

Practical Pitfalls to Avoid

• Do not use tPA/DNase as the initial therapy; reserve it for cases of inadequate drainage after chest‑tube placement 【1】.
• Do not contaminate pleural fluid pH samples with local anesthetic or heparin, as this alters the measurement 【1】.
• Do not proceed to early VATS or thoracotomy as the first‑line treatment unless specific indications exist 【1, 2】.

Monitoring & Chest‑Tube Management

• Remove the chest tube when drainage falls below 1 mL/kg per 24 hours and there is no air leak 【3】.

Management of Exudative Pleural Effusion with tPA/DNase

Indications and Mechanism of Action

• The British Thoracic Society recommends tPA/DNase for complicated pleural effusions associated with pleural infection where initial chest tube drainage is inadequate 4, 5
• DNase degrades the extracellular DNA that contributes to fluid viscosity, and when used in combination with tPA, is significantly more effective than either agent used alone 6, 5
• The combination of tPA and DNase works by breaking down fibrin deposits and degrading extracellular DNA, contributing to improved fluid drainage 7, 6

Clinical Benefits

• The American Thoracic Society suggests that tPA/DNase reduces length of hospital stay compared to placebo in pleural infection, with a significant reduction in hospital stay 4, 6
• tPA/DNase decreases likelihood of persistent fevers in infected pleural collections, and increases radiographic improvement with better clearance of pleural opacification 6, 5
• The use of tPA/DNase results in increased fluid drainage volume, with a median increase in drainage 4, 5

Administration Protocol

• The standard dosing regimen for tPA/DNase is 10mg tPA twice daily + 5mg DNase twice daily for 3 days, although alternative lower-dose regimens may be equally effective 4, 7, 8
• Administration is through an existing chest tube after initial drainage has slowed, and patient consent should be obtained due to potential bleeding risk 7, 6, 8

Important Considerations and Precautions

• tPA/DNase should NOT be used as single agents as they do not improve clinical outcomes when used individually, according to the European Respiratory Society 4, 6
• Reduced doses of tPA should be considered in patients with higher bleeding risk, such as those on therapeutic anticoagulation 7, 8

Alternative Approaches

• Saline irrigation can be considered when tPA/DNase therapy or surgery is not suitable, as recommended by the American College of Chest Physicians 4, 6
• Surgical intervention should be considered if medical management fails, with VATS preferred over thoracotomy 9, 10
• Streptokinase should NOT be used for treatment of pleural infection as it increases post-treatment complications with no improvement in outcomes, as stated by the British Thoracic Society 4, 6